Pluristem公司获美国FDA批准干细胞治疗阻滞动脉和缺血性结肠炎临床试验
2013-05-25 22:34:40 来源:
Pluristem wins FDA-EMEA approval for stem cell trials
The company will conduct a Phase II/III study of its product on blocked arteries, and a Phase II study on ischemia colitis.
18 January 11 15:17, Globes' correspondent
Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR; DAX: PJT) has successfully completed a parallel scientific advisory process with the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) for the planned clinical development program for its placenta-derived cell therapy, PLX-PAD, for blocked arteries in the limbs and heart.
The company said that it is now in a position to advance towards two clinical studies with its PLX-PAD cells: a joint FDA-EMEA Phase II/III study for critical limb ischemia (CLI) or severe blockage in the arteries; and a Phase II study for ischemia colitis (IC), or inflammation and injury of the large intestine result from inadequate blood supply, This study will be under the FDA and Germany's Paul Ehrlich Institute (PEI), which is the responsible authority in the EU.
Pluristem's placental cells do not cause rejection by either the mother's body or the fetus, and the company says that they cause little rejection when injected into another person's body. This minor reaction is in contrast to bone marrow derived stem cells, which have to be customized to the patient to prevent an immune reaction.
Pluristem chairman and CEO Zami Aberman said, “PLX-PAD has shown promise throughout its initial clinical development, and I am pleased that both the EMA and FDA have acknowledged our proposed comprehensive clinical development plan, which may lead to an advanced cell therapy product that could help millions of PAD patients."
He added, "The completion of two Phase-I CLI clinical studies, performed in parallel in Germany and the US, placed Pluristem in a unique position to discuss with the regulatory agencies an approach that should allow a single clinical study protocol to be accepted by both agencies.
“What is particularly exciting about this development is that it places us, for the first time, on track for a potentially preventative treatment for PAD in addition to treating amputation-destined cases."
Pluristem's share price rose 9.7% on TASE before trading was suspended, but fell back to a gain of 3.2% by the end of the session. The share rose 15.8% at the opening on Nasdaq to $3.15, after soared 29% in premarket trading, giving a market cap of $81 million.
Published by Globes [online], Israel business news - [url]www.globes-online.com[/url] - on January 18, 2011
The company will conduct a Phase II/III study of its product on blocked arteries, and a Phase II study on ischemia colitis.
18 January 11 15:17, Globes' correspondent
Pluristem Therapeutics Ltd. (Nasdaq:PSTI; TASE: PLTR; DAX: PJT) has successfully completed a parallel scientific advisory process with the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) for the planned clinical development program for its placenta-derived cell therapy, PLX-PAD, for blocked arteries in the limbs and heart.
The company said that it is now in a position to advance towards two clinical studies with its PLX-PAD cells: a joint FDA-EMEA Phase II/III study for critical limb ischemia (CLI) or severe blockage in the arteries; and a Phase II study for ischemia colitis (IC), or inflammation and injury of the large intestine result from inadequate blood supply, This study will be under the FDA and Germany's Paul Ehrlich Institute (PEI), which is the responsible authority in the EU.
Pluristem's placental cells do not cause rejection by either the mother's body or the fetus, and the company says that they cause little rejection when injected into another person's body. This minor reaction is in contrast to bone marrow derived stem cells, which have to be customized to the patient to prevent an immune reaction.
Pluristem chairman and CEO Zami Aberman said, “PLX-PAD has shown promise throughout its initial clinical development, and I am pleased that both the EMA and FDA have acknowledged our proposed comprehensive clinical development plan, which may lead to an advanced cell therapy product that could help millions of PAD patients."
He added, "The completion of two Phase-I CLI clinical studies, performed in parallel in Germany and the US, placed Pluristem in a unique position to discuss with the regulatory agencies an approach that should allow a single clinical study protocol to be accepted by both agencies.
“What is particularly exciting about this development is that it places us, for the first time, on track for a potentially preventative treatment for PAD in addition to treating amputation-destined cases."
Pluristem's share price rose 9.7% on TASE before trading was suspended, but fell back to a gain of 3.2% by the end of the session. The share rose 15.8% at the opening on Nasdaq to $3.15, after soared 29% in premarket trading, giving a market cap of $81 million.
Published by Globes [online], Israel business news - [url]www.globes-online.com[/url] - on January 18, 2011
上一篇:ACT公司获FDA批准进行胚胎干细胞治疗黄斑变性临床试验
下一篇:活细胞科技公司2010年度报告
延伸阅读:
- ·Pluristem公司和纽约大学医学中心合作研究使用PLX细胞治疗糖尿病足溃疡(2013-05-25)
- ·Pluristem干细胞疗法成功治疗癌症病人(2012-08-08)
- ·Pluristem公司:肌肉损伤的干细胞治疗取得阶段性成果(2014-01-24)
- ·Osiris公司提供开创性的I型糖尿病干细胞临床试验(2013-05-23)
- ·美国杰龙公司GRNOPC1治疗脊髓损伤安全性研究临床试验(2013-05-24)
分享到:
收藏
频道总排行
频道今日排行
- 3,5762014Q2——生物技术行业走上正轨
- 3,574iPS细胞缓步走向临床
- 3,573全球首例胚胎干细胞疗法试验夭折 成人干细胞研究进展良好
- 3,572哈佛干细胞专家:干细胞技术魅力在于让新药更低价
- 3,572争议干细胞疗法 意大利批准使用
- 3,572诺华敲定与干细胞公司Gamida的交易
- 3,572高丝利用iPS细胞开发化妆品?
- 3,572FDA 美国杜克大学医学院脐带血造血干细胞静脉注射悬浮液...
- 3,572十一位科学家获生命科学巨奖
- 3,571美国先进细胞科技公司开展干细胞治疗眼疾临床试验 效果显著